Research programme: microRNA based therapeutics - miRecule

Drug Profile

Research programme: microRNA based therapeutics - miRecule

Alternative Names: MIR 101; MIR-101 - miRecule

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator miRecule
  • Class MicroRNAs; Oligoribonucleotides; RNA binding proteins
  • Mechanism of Action MicroRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Head and neck cancer

Most Recent Events

  • 28 Sep 2016 Preclinical trials in Head and neck cancer in USA (Parenteral) before September 2016 (miRecule pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top